Recursion Pharmaceuticals, Inc. (RXRX)
3.34
-0.10
(-2.91%)
USD |
NASDAQ |
Aug 28, 16:00
3.33
-0.01
(-0.30%)
Pre-Market: 20:00
Recursion Pharmaceuticals Cash from Financing (Quarterly) : -1.267M for June 30, 2026
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.267M |
| March 31, 2026 | -3.47M |
| December 31, 2025 | 132.01M |
| September 30, 2025 | 251.34M |
| June 30, 2025 | 97.66M |
| March 31, 2025 | 40.53M |
| December 31, 2024 | 10.64M |
| September 30, 2024 | 16.46M |
| June 30, 2024 | 263.12M |
| March 31, 2024 | 13.90M |
| December 31, 2023 | 80.66M |
| September 30, 2023 | 53.76M |
| June 30, 2023 | 3.787M |
| Date | Value |
|---|---|
| March 31, 2023 | 1.922M |
| December 31, 2022 | 147.26M |
| September 30, 2022 | 2.337M |
| June 30, 2022 | 2.668M |
| March 31, 2022 | 2.084M |
| December 31, 2021 | 3.796M |
| September 30, 2021 | -11.10M |
| June 30, 2021 | 463.70M |
| March 31, 2021 | 2.134M |
| December 31, 2020 | 10.04M |
| September 30, 2020 | 229.72M |
| June 30, 2020 | 0.382M |
| March 31, 2020 | 5.997M |
Cash From Financing Definition
Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Twist Bioscience Corp. | 3.787M |
| Absci Corp. | 102.73M |
| Novavax, Inc. | 1.201M |
| Editas Medicine, Inc. | 117.54M |
| Halozyme Therapeutics, Inc. | -326.25M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -105.95M |
| Cash from Investing (Quarterly) | -1.959M |
| Free Cash Flow | -354.26M |
| Free Cash Flow Per Share (Quarterly) | -0.2027 |
| Free Cash Flow to Equity (Quarterly) | -102.17M |
| Free Cash Flow to Firm (Quarterly) | -107.60M |
| Free Cash Flow Yield | -20.84% |